Sustainability initiatives are launching across the biopharmaceutical industry as companies begin to scrutinize their environmental impacts as part of the growing environmental, social, and governance (ESG) movement in business. Achieving ambitious sustainability goals will require organizations to evaluate their raw materials, production processes, product packaging, operations, and supply and distribution chains — and such work will entail monumental effort. Herein, BPI managing editor Brian Gazaille speaks with Brian Fahie, head of analytical development at Biogen, about that company’s efforts to prioritize environmental concerns in its corporate culture and business dealings. A recognized leader of sustainability efforts in the biopharmaceutical industry, Biogen urges its fellow companies to take both a long-term vision and short-term approaches to establish sustainability momentum and keep it going. Reflecting on movements within his company, Fahie highlights the need for practicable, company-wide sustainability principles; company cultures that encourage innovation; and corporate agreements among drug developers, manufacturing partners, and industry suppliers. Read the complete eBook to learn about what aspects of biopharmaceutical development and manufacturing could be made more sustainable and how collaboration can realize improvements.
Fill out the form below to read the eBook now.
You May Also Like
